International Journal of Clinical Research

Objective To observe the difference between single chemotherapy and microtransplantation combined chemotherapy in high-risk patients with myelodysplastic syndrome. Methods Part of the study cases were selected from 16 patients with high-risk myelodysplastic syndrome admitted to our hospital from January 2019 to April 2022 to form the control group, all of whom received single chemotherapy. Observation group 8 patients were selected from other hospitals outside the province who were regularly followed up in our department after microtransplantation and chemotherapy combined treatment. The clinical efficacy, hematopoietic recovery time and survival of the two groups were evaluated. Results Compared with the control group, the total effective rate of the observation group increased more significantly (P < 0.05). Compared with the control group, the recovery time of neutrophil and platelet was significantly reduced in the observation group (P < 0.05). Compared with the control group, the 1-year and 2-year progression-free survival and overall survival of the observation group were higher than those of the control group (P < 0.05). Conclusion The combination of microtransplantation and chemotherapy can significantly improve the clinical efficacy and survival rate of patients with high-risk myelodysplastic syndrome.

High risk myelodysplastic syndrome; Chemotherapy; Micro-transplantation